They sketched out plans for what they described as an “exciting treatment” for children with the condition — a decades-old drug, leucovorin, newly recast as a potential breakthrough. “Hundreds of thousands of kids, in my opinion, will benefit,” Food and Drug Administration Commissioner Marty Makary said at the time. FDA announced Tuesday that it will expand approval for leucovorin, but only for a separate condition that some people with autism also have — not for autism itself. This week, however, FDA officials said leucovorin does not face a shortage. Whether physicians will keep prescribing leucovorin off-label for children with autism remains uncertain.

Source: Washington Post March 10, 2026 18:34 UTC